Ovarian Cancer
NEWS RELEASE
Released: January 30, 2017
Defense Health Program
Department of Defense Ovarian Cancer Research Program
Funding Opportunities for Fiscal Year 2017 (FY17)
Due to the current Continuing Resolution, the Fiscal Year 2017 (FY17) Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Ovarian Cancer Research Program (OCRP), the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.
FY17 OCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in February 2017. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the OCRP.
As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).
The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer. Although not required, investigators are encouraged to address one of the FY17 Areas of Encouragement in their applications.
- Novel therapies and associated predictive biomarkers
- Non-invasive surveillance and assessment of disease
- Treatment resistance
- Immunotherapy
- Etiology, epidemiology, and prevention
- Early detection
- Rare subtypes
- Host-tumor interactions
- Survivorship and quality of life
Award Mechanism | PI Eligibility | Key Mechanism Elements | Funding |
---|---|---|---|
Clinical Development Award | Must be an independent investigator at or above the level of Assistant Professor (or equivalent) |
|
|
Investigator-Initiated Research Award | Must be an independent investigator at or above the level of Assistant Professor (or equivalent) |
|
|
Ovarian Cancer Academy Award - Early-Career Investigator | Must be within 3 years of his/her last postdoctoral research position (Ph.D) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline. A letter attesting to eligibility is required. |
|
|
Pilot Award |
Established Investigator:
A letter attesting to eligibility is required. |
|
|
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil
Last updated Thursday, May 26, 2022